MLTX 2-DAY DEADLINE ALERT: MoonLake (MLTX) Class Action Lawsuit – Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms

Core Viewpoint - The lawsuit against MoonLake Immunotherapeutics alleges that the company and its executives made false statements about the clinical efficacy of their drug candidate, sonelokimab, leading to a significant stock price drop of nearly 90% following disappointing trial results [2][3][4]. Summary by Sections Lawsuit Details - The lawsuit claims that MoonLake's assertions regarding the superiority of its Nanobody technology were misleading, particularly in comparison to the FDA-approved competitor BIMZELX [3]. - The stock price plummeted from $61.99 to $6.24, representing a 90% loss, after the VELA-2 trial failed to meet its primary endpoint and demonstrated inferior efficacy [4]. Timeline and Key Information - Class Period: March 10, 2024 – September 29, 2025 - Lead Plaintiff Deadline: December 15, 2025 - Significant Stock Drop: 90% loss on September 29, 2025, due to failed trial results [4]. Next Steps for Investors - Investors who purchased MoonLake stock during the specified class period and incurred substantial losses are encouraged to contact Hagens Berman to explore legal options and potential appointment as Lead Plaintiff [5]. About Hagens Berman - Hagens Berman is a global plaintiffs' rights firm that focuses on corporate accountability and has secured over $2.9 billion for clients in similar cases [7].